PolyMedix Reschedules Webcast for Wednesday, April 7 at 10:00 AM

Management to Review Results from Phase 1B Clinical Study with Novel Antibiotic, PMX-30063

RADNOR, Pa.--(BUSINESS WIRE)--Apr 6, 2010 - PolyMedix, Inc. (OTC BB: PYMX), an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has rescheduled its webcast for Wednesday, April 7 at 10:00 AM Eastern Time. At that time, management will review the results from the recently completed Phase 1B clinical study with PMX-30063, PolyMedix's novel defensin-mimetic antibiotic.

A live webcast may be accessed on PolyMedix's website at www.polymedix.com or at http://investor.shareholder.com/media/eventdetail.cfm?eventid=79828&CompanyID=ABEA-4ITCYZ&e=1&mediaKey=AA30477493DD80F026CCF4C7874D5D89. An archive of the event will be available on either site approximately two-hours after the event.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of acute cardiovascular disorders and infectious diseases. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, PolyMedix's heptagonist compound, is being developed to reverse the activity of both heparin and low molecular weight heparins. PolyMedix plans to develop an antagonist drug that is safer and easier to use than currently approved therapy. PMX-30063, PolyMedix's antibiotic compound is a small molecule that mimics human host-defense proteins and has a completely different mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. PolyMedix's goal is to develop this compound as a rapidly acting antibiotic for serious systemic and local infections. Both PMX-60056 heptagonist and PMX-30063 antibiotic are currently undergoing clinical testing. PolyMedix also plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. For more information, please visit PolyMedix on its website at www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements, PolyMedix's compounds may not enter or successfully complete clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

 

Contact: PolyMedix, Inc.
Lisa Caperelli
Director, Investor Relations & Corporate Communications
484-598-2406
lcaperelli@polymedix.com
or
Investor Relations Group, Inc.
Investors:
Erika Moran
emoran@investorrelationsgroup.com
or
Media:
Janet Vasquez
jvasquez@investorrelationsgroup.com
212-825-3210

 

Posted: April 2010

View comments

Hide
(web1)